Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPX-501 and Rimiducid in Pediatric Hematologic Malignancies
NCT03459170Phase 1Active, not recruiting
- Sponsor
- Bellicum Pharmaceuticals, Inc.
- Start
- Feb 2018
- Primary completion
- Sep 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivogenlecleucel in hematologic malignancy (3 arms), sponsored by Bellicum Pharmaceuticals, Inc. Primary endpoints: BPX-501 Safety at Month 24 and Mean plasma concentration of Rimiducid at 8 hours. Started Feb 2018; status: active, not recruiting.
02
Drugs
rivogenlecleucel
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT03459170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459170.